Krystal Biotech (KRYS) EPS (Basic) (2016 - 2026)

Krystal Biotech has disclosed EPS (Basic) across 11 years of filings, most recently posting $1.91 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $1.91, up 54.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.75 (up 79.4% YoY), and the FY2025 annual result was $7.08, up 126.92% from the prior year.
• EPS (Basic) came in at $1.91 for Q1 2026 at Krystal Biotech, up from $1.77 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $2.88 in Q3 2023 to a low of -$1.99 in Q1 2022.
• The 5-year median for EPS (Basic) is $0.54 (2024), against an average of $0.4.
• Across the five-year window, EPS (Basic) sank 168.92% in 2022 and jumped 4033.33% in 2025, its largest moves.
• Krystal Biotech's EPS (Basic) stood at -$1.25 in 2022, then jumped by 125.6% to $0.32 in 2023, then surged by 396.88% to $1.59 in 2024, then increased by 11.32% to $1.77 in 2025, then increased by 7.91% to $1.91 in 2026.
• The last three EPS (Basic) figures came in at $1.91 (Q1 2026), $1.77 (Q4 2025), and $2.74 (Q3 2025), per Business Quant data.